| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Full-Year Revenue Guidance Hike Drove Alpha Teknova (TKNO) Higher | 3 | Insider Monkey | ||
| 22.10. | Alpha Teknova, Inc.: Teknova to Report Third Quarter 2026 Financial Results on November 4, 2026 | 4 | GlobeNewswire (USA) | ||
| 21.10. | Alpha Teknova, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| ALPHA TEKNOVA Aktie jetzt für 0€ handeln | |||||
| 21.10. | Morning Market Movers: Robin Energy, Olenox Industries, Ashford Hospitality Trust, Alpha Teknova See Big Swings | 543 | AFX News | BEIJING (dpa-AFX) - At 7:50 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| 21.10. | Alpha Teknova prices $40M stock offering at $5 per share | 2 | Seeking Alpha | ||
| 21.10. | Alpha Teknova Shares Sink 23% After Hours: Here's Why | 3 | Benzinga.com | ||
| 21.10. | Alpha Teknova prices $40 million stock offering at $5/share | 3 | Investing.com | ||
| 20.10. | Alpha Teknova-Aktie bricht nach Ankündigung einer Kapitalerhöhung ein | 1 | Investing.com Deutsch | ||
| 20.10. | Teknova reports preliminary Q3 revenue of $12.5-12.7 million | 1 | Investing.com | ||
| 20.10. | Alpha Teknova launches public offering of common stock | 1 | Investing.com | ||
| 20.10. | Alpha Teknova reports Preliminary Q3 results | 1 | Seeking Alpha | ||
| 02.10. | Alpha Teknova, Inc.: Teknova and Pluristyx Announce FDA Drug Master File for the PluriFreeze Cryopreservation System | 351 | GlobeNewswire (Europe) | HOLLISTER, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (Nasdaq: TKNO), and Pluristyx, Inc. ("Pluristyx"), today announced that Pluristyx is completing a Type II Drug... ► Artikel lesen | |
| 24.09. | Biotech Stocks At 52-Week Highs - Alpha Teknova, Moderna, AtriCure, Illumina | 1.252 | AFX News | SAN DIEGO (dpa-AFX) - The following biotech stocks reached a 52-week high on September 23, 2026, driven by key catalysts such as positive quarterly reports or results from clinical trials.Alpha... ► Artikel lesen | |
| 17.09. | Jefferies startet Coverage für Alpha Teknova mit Kaufempfehlung und verweist auf Wachstumsausblick | 2 | Investing.com Deutsch | ||
| 17.09. | Jefferies initiates Alpha Teknova stock with buy on growth outlook | 1 | Investing.com | ||
| 16.09. | Teknova launches Fill-Tek dispensing system for custom reagents | 1 | Investing.com | ||
| 16.09. | Teknova führt Fill-Tek-Abfüllsystem für kundenspezifische Reagenzien ein | 2 | Investing.com Deutsch | ||
| 16.09. | Alpha Teknova, Inc.: Teknova Expands Custom Manufacturing with Fill-Tek Dispensing System for Flexible Single-Use Bag Filling | 1 | GlobeNewswire (USA) | ||
| 24.08. | Alpha Teknova: Teure Produktionsreserven - lohnt das Warten auf die Margenwende? | 408 | ARIVA.de | Alpha Teknova verfügt über erhebliche freie Produktionskapazitäten, erzielt derzeit jedoch nur geringe Margen und rechtfertigt damit die aktuelle Bewertungsprämie nur bedingt. Der von Seeking Alpha... ► Artikel lesen | |
| 19.08. | Alpha Teknova: Klinisches Wachstum im Fokus, Profitabilität in Reichweite | 2 | Investing.com Deutsch |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CLINUVEL | 4,451 | -1,13 % | Clinuvel Pharmaceuticals Ltd - 20-F, Annual and transition report of foreign private issuers | ||
| BIOCRYST PHARMACEUTICALS | 7,590 | +0,37 % | BioCryst Pharmaceuticals, Inc.: BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and Growth | -Supports BioCryst's evolution toward a more disciplined R&D model centered on external innovation- RESEARCH TRIANGLE PARK, N.C., Oct. 05, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 1,062 | +5,57 % | BioNTech sucht den Durchbruch mit der Krebs-Pipeline, DroneShield kämpft gegen Shortseller und Cardiol Therapeutics visiert den Rebound an! | Erstellt und veröffentlicht im Auftrag von Cardiol Therapeutics Biotech-Größen wie z. B. BioNTech und Rüstungs- und Drohnenwerte wie DroneShield suchen aktuell nach eindeutigen und klaren Trendsignalen.... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 3,840 | +1,59 % | Arbutus Biopharma Corporation: Arbutus Announces Final Results of Its US$230 Million Modified "Dutch Auction" Tender Offer | WARMINSTER, Pa., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company focused on infectious disease... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 0,795 | 0,00 % | Cardiff Oncology ernennt Dr. Leila Alland zur Interims-Chief-Medical-Officer | ||
| ALDEYRA | 0,498 | 0,00 % | H.C. Wainwright bestätigt Aldeyra-Aktie mit "Neutral" und Kursziel von 2 US-Dollar | ||
| DENALI THERAPEUTICS | 16,965 | -0,41 % | Denali Therapeutics Inc.: Denali Therapeutics Receives 2026 Prix Galien USA Award for AVLAYAH (tividenofusp alfa-eknm) as Best Biotechnology Product | ||
| ABCELLERA BIOLOGICS | 10,960 | -0,36 % | Jefferies nimmt AbCellera mit "Buy" auf - Kursziel 21,00 $ | ||
| ADAPTIVE BIOTECHNOLOGIES | 24,950 | +4,66 % | Adaptive Biotechnologies Highlights Role of Highly Sensitive MRD Testing in New International Myeloma Society Definition of Cure | SEATTLE, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune... ► Artikel lesen | |
| AC IMMUNE | 2,070 | +4,44 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 19.10.2026 | Folgende Wertpapiere werden in den Handel an der Frankfurter Wertpapierbörse (FWB) aufgenommen.
1. US88025U1097 10X GENOMICS INC
2. NL0000852564 AALBERTS NV
3. SE0016589188 ELECTROLUX AB
4. SE0000115446... ► Artikel lesen | |
| COHERUS ONCOLOGY | 0,735 | -1,87 % | Coherus Oncology, Inc. - 8-K, Current Report | ||
| HELUS PHARMA | 9,550 | +1,38 % | Helus Pharma Inc: Helus Pharma appoints Lawson as chair | ||
| CYTOMX THERAPEUTICS | 2,072 | -0,48 % | CytomX Therapeutics Inc.: CytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan ("Varseta-M") for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC) | - Fast Track Designation follows encouraging Phase 1 data that were previously reported for R/R mCRC - - Potential Varseta-M monotherapy registrational study in R/R mCRC planned for initiation in... ► Artikel lesen | |
| AGENUS | 6,450 | +4,88 % | Agenus Inc.: Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026 | The cohort met its primary endpoint of major pathologic response, with 83% of patients having little or no cancer remaining at surgery in a high-risk, locally advanced population Side effects... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 11,000 | -0,27 % | Transcript: Arcturus Therapeutics Q2 2026 Earnings Conference Call |